Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

The broadly neutralizing antibody (bNAb) CAP256-VRC26.25 has exceptional potency against HIV-1 and has been considered for clinical use. During the characterization and production of this bNAb, we observed several unusual features. First, the antibody appeared to adhere to pipette tips, requiring ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Baoshan, Gollapudi, Deepika, Gorman, Jason, O’Dell, Sijy, Damron, Leland F., McKee, Krisha, Asokan, Mangaiarkarasi, Yang, Eun Sung, Pegu, Amarendra, Lin, Bob C., Chao, Cara W., Chen, Xuejun, Gama, Lucio, Ivleva, Vera B., Law, William H., Liu, Cuiping, Louder, Mark K., Schmidt, Stephen D., Shen, Chen-Hsiang, Shi, Wei, Stein, Judith A., Seaman, Michael S., McDermott, Adrian B., Carlton, Kevin, Mascola, John R., Kwong, Peter D., Lei, Q. Paula, Doria-Rose, Nicole A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596707/
https://www.ncbi.nlm.nih.gov/pubmed/36284200
http://dx.doi.org/10.1038/s41598-022-22435-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596707/
https://www.ncbi.nlm.nih.gov/pubmed/36284200
http://dx.doi.org/10.1038/s41598-022-22435-2

Ejemplares similares